Literature DB >> 8624110

Metabotropic glutamate receptors regulate APP processing in hippocampal neurons and cortical astrocytes derived from fetal rats.

R K Lee1, J Jimenez, A J Cox, R J Wurtman.   

Abstract

It has previously been shown that stimulation of muscarinic m1 or m3 receptors can, by generating diacylglycerol (DAG) and activating protein kinase C (PKC), accelerate the breakdown of the amyloid precursor protein (APP) to form soluble, non-amyloidogenic peptides (APPs). This relationship has been demonstrated in human glioma and neuroblastoma cells as well as in transfected human embryonic kidney (HEK) cells and PC12 cells. We now provide evidence that stimulation of metabotropic glutamate receptors (mGluRs), which also are coupled to DAG and PKC, similarly accelerates processing of APP into non-amyloidogenic APPs in hippocampal neurons and cortical astrocytes derived from normal fetal rats. The mGluR antagonist, L(+)-2-amino-3-phosphonopropionic acid (L-AP3), and GF 109203X, an inhibitor of PKC, both blocked the release of APPs from hippocampal neurons and astrocytes evoked by glutamate receptor stimulation. Inasmuch as glutamatergic neurons in cortex and hippocampus are known to be damaged in Alzheimer's disease, our findings suggest that amyloid formation may be enhanced by the resulting glutamate deficiency and that selective mGluR agonists may be useful in facilitating synaptic efficacy and treating the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8624110     DOI: 10.1111/j.1749-6632.1996.tb34443.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

Review 1.  Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Brain Res Brain Res Rev       Date:  2005-01-08

2.  mGluRI targets microglial activation and selectively prevents neuronal cell engulfment through Akt and caspase dependent pathways.

Authors:  Zhao Zhong Chong; Jingqiong Kang; Faqi Li; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2005-07       Impact factor: 1.990

Review 3.  Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better?

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2005-01       Impact factor: 1.990

Review 4.  Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology.

Authors:  Timothy J Revett; Glen B Baker; Jack Jhamandas; Satyabrata Kar
Journal:  J Psychiatry Neurosci       Date:  2013-01       Impact factor: 6.186

Review 5.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

6.  AMPA receptor activation promotes non-amyloidogenic amyloid precursor protein processing and suppresses neuronal amyloid-β production.

Authors:  Sarah E Hoey; Federica Buonocore; Carla J Cox; Victoria J Hammond; Michael S Perkinton; Robert J Williams
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

7.  Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer's disease.

Authors:  Isidro Ferrer; Pol Andrés-Benito; Karina Ausín; Reinald Pamplona; José Antonio Del Rio; Joaquín Fernández-Irigoyen; Enrique Santamaría
Journal:  Brain Pathol       Date:  2021-07-04       Impact factor: 6.508

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.